Trial Profile
Phase I study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 and intraperitoneal infusion of nafamostat mesilate for gastric cancer with peritoneal dissemination
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 16 Feb 2021
Price :
$35
*
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary) ; Nafamostat (Primary) ; Paclitaxel (Primary) ; Paclitaxel (Primary)
- Indications Adenocarcinoma; Cancer metastases; Gastric cancer
- Focus Adverse reactions
- 14 Feb 2021 Status changed from recruiting to discontinued.
- 04 Sep 2015 New trial record